Obstetrical factors and the transmission of human immunodeficiency virus type I from mother to child

New England Journal of Medicine

Volumn 334, Issue 25, 1996, Pages 1617-1623

  Landesman, Sheldon H ^a   Kalish, Leslie A ^b   Burns, David N ^c   Minkoff, Howard ^a   Fox, Harold E ^d   Zorrilla, Carmen ^e   Garcia, Pat ^f   Fowler, Mary Glenn ^g   Mofenson, Lynne ^c   Tuomala, Ruth ^h  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^f NORTHWESTERN UNIVERSITY   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FEMALE; FETOMATERNAL TRANSFUSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; OBSTETRIC CARE; PRIORITY JOURNAL; VIRUS TRANSMISSION;

ADULT; CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION, VERTICAL; FEMALE; FETAL MEMBRANES, PREMATURE RUPTURE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; REPRODUCTIVE HISTORY; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS;

EID: 0030013531     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199606203342501     Document Type: Article

References (58)

1. St Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993;269:2853-9.
2. Burns DN, Landesman SH, Muenz LR, et al. Cigarette smoking, premature rupture of membranes and vertical transmission of HIV-1 among women with low CD4+ levels. J Acquir Immune Dene Syndr 1994;7:718-26.
3. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992;339:1007-12.
4. Lallemant M, Baillou A, Lallemant-Le Couer S, et al. Maternal antibody response at delivery and perinatal transmission of human immunodeficiency virus type 1 in African women. Lancet 1994;343:1001-5.
5. Lindgren S, Anzen B, Bohlin A, Lidman K. HIV and child-bearing: clinical outcome and aspects of mother-to-infant transmission. AIDS 1991;5:1111-6.
6. Gabiano C, Tovo PA, de Martino M, et al. Mother-to-child transmission of human immunodeficiency virus type 1: risk of infection and correlates of transmission. Pediatrics 1992;90:362-74.
7. Ryder RW, Nsa W, Hassig SE, et al. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. N Engl J Med 1989;320:1637-42.
8. Rossi P, Moschese V, Wigzell H, Broliden PA, Wahren B. Mother-to-infant transmission of HIV. Lancet 1990;335:359-60.
9. Goedert JJ, Mendez H, Drummond JE, et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet 1989;2:1351-4.
10. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci U S A 1990;87:3445-9. [Erratum, Proc Natl Acad Sci U S A 1991;88:1084.]
11. Ugen KE, Goedert JJ, Boyer J, et al. Vertical transmission of human immunodeficiency virus (HIV) infection: reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 1992;89:1923-30.
12. Halsey NA, Markham R, Wahren B, Boulos R, Rossi P, Wigzell H. Lack of association between maternal antibodies to V3 loop peptides and maternal-infant HIV-1 transmission. J Acquir Immune Defic Syndr 1992;5: 153-7.
13. Minkoff H, Burns DN, Landesman SH, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995;173:585-9.
14. European Collaborative Study. Caesarean section and risk of vertical transmission of HIV-1 infection. Lancet 1994;343:1464-7.
15. Kuhn L, Stein ZA, Thomas PA, Singh T, Tsai WY. Maternal-infant HIV transmission and circumstances of delivery. Am J Public Health 1994;84:1110-5.
16. Duliège A-M, Amos CI, Felton S, Biggar RJ, International Registry of HIV-Exposed Twins, Goedert JJ. Birth order, delivery route, and concordance in the transmission of human immunodeficiency virus type 1 from mothers to twins. J Pediatr 1995;126:625-32.
17. Goedert JJ, Duliege AM, Amos CI, Felton S, Biggar RJ. High risk of HIV-1 infection for first-born twins. Lancet 1991;338:1471-5.
18. Krivine A, Firtion G, Cao L, Francoual C, Henrion R, Lebon P. HIV replication during the first weeks of life. Lancet 1992;339:1187-9.
19. Ehrnst A, Lindgren S, Dictor M, et al. HIV in pregnant women and their offspring: evidence for late transmission. Lancet 1991;338:203-7.
20. Burgard M, Mayaux M-J, Blanche S, et al. The use of viral culture and p24 antigen testing to diagnose human immunodeficiency virus infection in neonates. N Engl J Med 1992;327:1192-7.
21. Hollinger FB. Bremer JW, Myers LE, Gold JWM, McQuay L, NIH/NIAID/ DAIDS/ACTG Virology Laboratories. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. J Clin Microbiol 1992;30:1787-94.
22. Hollinger FB, Bremer JW, Myers L, Gupta P, Meyer W. HIV quantitation by dilutional microculture: development, standardization, and quality control implementation in a multicenter clinical trials setting: ACTG virology quantitative working group. In: Abstracts of the Eighth International Conference on AIDS/Third STD World Congress, Amsterdam, July 19-24, 1992. Vol. 1. Amsterdam: CONGREX, 1992:23. abstract.
23. McIntosh K, Pitt J, Brambilla D, et al. Blood culture in the first 6 months of life for the diagnosis of vertically transmitted human immunodeficiency virus infection. J Infect Dis 1994;170:996-1000.
24. Peterson PK, Gekker G, Chao CC, Schul R, Molitor TW, Balfour HH Jr. Cocaine potentiates HIV-1 replication in human peripheral blood mononuclear cell cocultures: involvement of transforming growth factor-beta. J Immunol 1991;146:81-4.
25. Peterson PK, Sharp BM, Gekker G, Portoghese PS, Sannerud K, Balfour HH Jr. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990;4:869-73.
26. Bagasra O, Pomerantz RJ. Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. J Infect Dis 1993;168:1157-64.
27. Taylor JMG, Fahey JL, Detelo R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24.
28. Kidd PG, Cheng S-C, Paxton H, Landay A, Gelman R. Prediction of CD4 count from CD4 percentage: experience from three laboratories. AIDS 1993;7:933-40.
29. Schafer DF, Piskac A, Kennedy K, et al. Decreased levels of helper T cells in pregnancy. N Engl J Med 1982;307:1582-3.
30. Talion DF, Corcoran DJD, O'Dwyer EM, Greally JF. Circulating lymphocyte subpopulations in pregnancy: a longitudinal study. J Immunol 1984; 132:1784-7.
31. Cleveland WS. Robust locally weighted regression and smoothing scatter-plots. J Am Stat Assoc 1979;74:829-36.
32. Mehta CR, Patel NR. A network algorithm for performing Fisher's exact test in r x c contingency tables. J Am Stat Assoc 1983;78:427-34.
33. Agresti A. Categorical data analysis. New York: John Wiley, 1990.
34. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley, 1989.
35. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
36. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1: preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994;271:1925-30.
37. Rodriguez EM, Vermund SH. Maternal drug use and pediatric HIV infection: a methodologic review, Pediatr AIDS HIV Infect Fetus to Adolescent 1991;3:107-22.
38. Mayaux M-J. Blanche S, Rouzioux C, et al. Maternal factors associated with perinatal HIV-1 transmission: the French Cohort Study: 7 years of follow-up observation. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:188-94.
39. Nesheim SR, Lindsay M, Sawyer MK, et al. A prospective population-based study of HIV perinatal transmission. AIDS 1994;8:1293-8.
40. Rodriquez EM, Mofenson LM, Chang B-H. et al. Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission in the Women and Infants Study. AIDS 1996;10: 273-82.
41. Mofenson LM. Epidemiology and determinants of vertical HIV transmission. Semin Pediatr Infect Dis 1994;5:252-65.
42. Nair P, Alger L, Hines S, Sieden S, Hebel R, Johnson JP. Maternal and neonatal characteristics associated witn HIV infection in infants of seropositive women. J Acquir Immune Dene Syndr 1993;6:298-302.
43. Abrams EJ, Matheson PB, Thomas PA, et al. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. Pediatrics 1995;96:451-8.
44. Lepage P, Van de Perre P, Msellati P, et al. Mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) and its determinants: a cohort study in Kigali, Rwanda. Am J Epidemiol 1993;137:589-99.
45. Lepage P, Msellati P, Van de Perre P, Hitimana DG, Dabis F. Characteristics of newborns and HIV-1 infection in Rwanda. AIDS 1992;6:882-3.
46. The European Collaborative Study. Perinatal findings in children born to HIV-infected mothers. Br J Obstet Cynaecol 1994;101:136-41.
47. Minkoff H. Mofenson LM. The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. Am J Obstet Gynecol 1994;171:1167-75.
48. Rogers MF, Ou C-Y, Rayfield M, et al. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. N Engl J Med 1989;320:1649-54.
49. Rogers MF, Ou C-Y, Kilbourne B, Schochetman G. Advances and problems in the diagnosis of human immunodeficiency virus infection in infants. Pediatr Infect Dis J 1991;10:523-31.
50. Henin Y, Mandelbrot L, Henrion R, Pradinaud R, Coulaud JP, Montagnier L. Virus excretion in the cervicovaginal secretions of pregnant and nonpregnant HIV-intected women. J Acquir Immune Defic Syndr 1993;6:72-5.
51. Clemetson DB, Moss GB, Willerford DM, et al. Detection of HIV DNA in cervical and vaginal secretions: prevalence and correlates among women in Nairobi, Kenya. JAMA 1993;269:2860-4.
52. Dickover RE, Garratty EM, Herman SA, et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599-605.
53. Villari P, Spino C, Chalmers TC, Lau J, Sacks HS. Cesarean section to reduce perinatal transmission of human immunodeficiency virus: a metaanalysis. Online J Curr Clin Trials 1993 July 8;Doc. no. 74:[5107 words; 46 paragraphs].
54. Dunn DT, Newell ML, Mayaux MJ, et al. Mode of delivery and vertical transmission of HIV-1: a review of prospective studies. J Acquir Immune Defic Syndr 1994;7:1064-6.
55. Mofenson LM. A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. Pediatr Infect Dis J 1995;14:169-77.
56. Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1994;43(RR-11):1-20.
57. Sachs BP, McCarthy BJ, Rubin G, Burton A, Terry J, Tyler CW Jr. Cesarean section: risk and benefits for mother and fetus. JAMA 1983;250:2157-9.
58. Semprini AE, Castagna C, Ravizza M, et al. The incidence of complications after cesarean section in 156 HIV-positive women. AIDS 1995;9:913-7.